DB06034InvestigationalSmall molecule
Investigated for use/treatment in solid tumors.
- Mechanism
- Curator reviewed
ARQ 171 is designed to kill cancer cells selectively while sparing normal cells through the direct activation of DNA damage response/checkpoint pathways believed to be regulated by the E2F-1 regulatory protein, thereby restoring the ability of the cell to recognize DNA damage and initiating the process of apoptosis, or programmed cell death, in these cells..
- Primary indication
- Investigated for use/treatment in solid tumors.Curator reviewed
- Code names
- ARQ 171
What you can answer from here — as of April 02, 2025
Which companies are running trials of ARQ 171, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account